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Abstract
Background: It is not known whether the addition of chemotherapy to radiation therapy improves outcomes in primary
vaginal cancer. Here, we review clinical outcomes in patients with primary vaginal cancer treated with radiation therapy (RT)
or concurrent chemoradiation therapy (CRT).
Methods: Seventy-one patients with primary vaginal cancer treated with definitive RT with or without concurrent
chemotherapy at a single institution were identified and their records reviewed. A total of 51 patients were treated with RT
alone; 20 patients were treated with CRT. Recurrences were analyzed. Overall survival (OS) and disease-free survival (DFS)
rates were estimated using the Kaplan-Meier method. Cox regression analysis was performed.
Results: The median age at diagnosis was 61 years (range, 18–92 years) and the median follow-up time among survivors
was 3.0 years. Kaplan-Meier estimates for OS and DFS differed significantly between the RT and CRT groups (3-yr OS= 56%
vs. 79%, log-rank p= 0.037; 3-yr DFS = 43% vs. 73%, log-rank p = 0.011). Twenty-three patients (45%) in the RT group had a
relapse at any site compared to 3 (15%) in the CRT group (p= 0.027). With regard to the sites of first relapse, 10 patients
(14%) had local only, 4 (6%) had local and regional, 9 (13%) had regional only, 1 (1%) had regional and distant, and 2 (3%)
had distant only relapse. On univariate analysis, the use of concurrent chemotherapy, FIGO stage, tumor size, and date of
diagnosis were significant predictors of DFS. On multivariate analysis, the use of concurrent chemotherapy remained a
significant predictor of DFS (hazard ratio 0.31 (95% CI, 0.10–0.97; p = 0.04)).
Conclusions: Vaginal cancer results in poor outcomes. Adequate radiation dose is essential to ensure curative management.
Concurrent chemotherapy should be considered for vaginal cancer patients.
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Introduction
Vaginal cancer is a rare disease, comprising only 1%–2% of all
gynecologic malignancies. Known prognostic factors for recur-
rence of vaginal cancer include stage, lymph node involvement
[1,2], size of the initial lesion [3] and advanced age [4]. Location
of the lesion, grade, and HPV status have conflicting evidence [5].
The standard treatment for non-metastatic vaginal cancer has
historically consisted of definitive radiation therapy (RT) alone,
using external-beam radiation therapy (EBRT) with or without
brachytherapy [6,7,8]. Optimal outcomes are achieved with
careful selection of treatment modalities to ensure coverage of
the tumor and involved regions. Over the past two decades, the
integration of computed tomography (CT) and magnetic reso-
nance imaging (MRI) for staging has allowed more accurate
assessment of nodal involvement and appropriate treatment to
suspicious lymph node regions. Similarly, 3-dimensional (3D)
imaging used for radiation planning has facilitated the identifica-
tion and delineation of the target volume with greater accuracy
[9].
Given the favorable outcome of cervical cancer patients treated
with chemoradiation therapy (CRT) [10,11], translation to vaginal
cancer remains a topic of discussion. Studies published to date
address the feasibility and outcomes of CRT for primary vaginal
cancer, but have few patients and therefore comparisons to RT
alone are limited [12,13,14]. In this study, we analyze and
compare the clinical outcomes of patients with primary vaginal
cancer treated at our institution with either definitive RT or with
CRT.
Patients and Methods
Patients
Records of patients with a diagnosis of biopsy-proven primary
vaginal cancer treated with definitive RT with or without
concurrent chemotherapy at Brigham & Women’s Hospital/
Dana-Farber Cancer Institute between 1972 and 2009 were
identified and retrospectively reviewed under an Institutional
Review Board (Dana-Farber Cancer Institute IRB)-approved
protocol with a waiver of consent. Exclusion criteria were prior
gynecological malignancy, prior pelvic radiation therapy, meta-
static disease and cancer involvement of the cervix or vulva. For all
patients, pretreatment patient and tumor characteristics were
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Table 1. Patient and tumor characteristics.
Category Subcategory All patients (n=71) RT alone (n=51) ChemoRT (n=20) p value
Median follow-up (range) All patients 2.3 years (0.3–14.6) 2.3 years (0.5–14.6) 2.6 years (0.3–7.76) 0.625
Survivors 3.0 years (0.3–14.6) 3.0 years (0.7–14.6) 3.6 years (0.3–7.8) 0.462
Median Age (range) All patients 61 (18–92) 64 (20–92) 60 (18–81) 0.112
Year of diagnosis 1970–1979 8 (11%) 8 (16%) 0 (0%) ,0.001
1980–1989 14 (20%) 13 (26%) 1 (5%)
1990–1999 17 (24%) 16 (32%) 1 (5%)
2000–2009 32 (45%) 14 (28%) 18 (90%)
Stage (FIGO) I 22 (31%) 18 (35%) 4 (20%) 0.395
II 30 (42%) 19 (37%) 11 (55%)
III 12 (17%) 8 (16%) 4 (20%)
IVA 7 (10%) 6 (12%) 1 (5%)
Prior hysterectomy No 33 (47%) 21 (41%) 12 (60%) 0.191
Yes 38 (54%) 30 (59%) 8 (40%)
Diagnostic imaging No 30 (42%) 29 (57%) 1 (5%) ,0.001
Yes 41 (58%) 22 (43%) 19 (95%)
CT 21 (30%) 16 (31%) 5 (25%)
MRI 9 (13%) 2 (4%) 7 (35%)
PET 1 (1%) 1 (2%) 0 (0%)
CT and MRI 4 (6%) 1 (2%) 3 (15%)
MRI and PET 5 (7%) 1 (2%) 4 (20%)
CT and PET 1 (1%) 1 (2%) 0 (0%)
Tumor size #4 cm 41 (58%) 27 (53%) 14 (70%) 0.202
.4 cm 24 (34%) 18 (35%) 6 (30%)
Unknown 6 (9%) 6 (12%) 0 (0%)
Tumor site Apex 15 (21%) 12 (24%) 3 (15%) 0.055
Upper 2/3 39 (55%) 31 (61%) 8 (40%)
Lower 1/3 10 (14%) 4 (8%) 6 (30%)
Entire 6 (9%) 4 (8%) 2 (10%)
Unknown 1 (1%) 0 (0%) 1 (5%)
Histology Squamous cell 54 (76%) 36 (71%) 18 (90%) 0.384
Adenocarcinoma 7 (10%) 7 (14%) 0 (0%)
Clear cell 5 (7%) 4 (8%) 1 (5%)
Epidermoid 2 (3%) 2 (4%) 0 (0%)
Unknown 2 (3%) 1 (2%) 1 (5%)
Other 1 (1%) 1 (2%) 0 (0%)
Differentiation Well 10 (14%) 9 (18%) 1 (5%) 0.116
Moderately 18 (25%) 15 (29%) 3 (15%)
Poorly 25 (35%) 14 (28%) 11 (55%)
Unknown 18 (25%) 13 (26%) 5 (25%)
LVI No 10 (14%) 7 (14%) 3 (15%) 0.923
Yes 5 (7%) 3 (6%) 2 (10%)
Unknown 56 (79%) 41 (80%) 15 (75%)
Lymph node involvement None 61 (86%) 48 (94%) 13 (65%) 0.004
Pelvic 4 (6%) 2 (4%) 2 (10%)
Inguinal 2 (3%) 0 (0%) 2 (10%)
Pelvic and inguinal 1 (1%) 1 (2%) 0 (0%)
Para-aortic 3 (4%) 0 (0%) 3 (15%)
Key: CRT, concurrent chemoradiation; FIGO, Federation Internationale de Gynecologie et Obstetrique; CT, computed tomography; MRI, magnetic resonance imaging;
PET, positron emission tomography; LVI, lymphatic vessel invasion.
doi:10.1371/journal.pone.0065048.t001
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recorded, including date of diagnosis, stage according to the
International Federation of Gynecology and Obstetrics (FIGO)
2000 classification, histology, tumor size, tumor site, tumor
differentiation, presence of lymphatic vessel invasion (LVI) and
lymph node involvement. For each patient, medical records were
reviewed to determine whether diagnostic imaging, including
pelvic CT, pelvic MRI and PET scan, had been performed to
evaluate for lymph node involvement and/or distant metastases.
Treatment
Treatment characteristics for all patients were recorded,
including the type of radiation therapy used (EBRT, brachyther-
apy, or both), EBRT technique, brachytherapy type and dose rate,
treatment duration, and the use of chemotherapy. For patients
treated with high-dose-rate (HDR) brachytherapy, the total
radiation dose was converted to the biologically equivalent dose
(BED) in 2-Gy fractions, using the linear quadratic BED equation
with an a/b ratio of 10. For patients treated with CRT, the type of
chemotherapy used and the number of cycles of chemotherapy
were recorded. Information was also collected on whether surgery
was performed and the type of surgery.
Clinical Outcomes
Data on outcomes were collected for each patient, including
local, regional and distant relapse, disease-free survival (DFS) and
overall survival (OS). Local relapse was defined as recurrence in the
vagina or paravaginal area. Regional relapse was defined as
recurrence in the pelvic or inguinal lymph nodes. Distant relapse
included para-aortic recurrences and distant metastases.
Statistical Analysis
We report medians with interquartile range or means with
standard deviation for numeric variables and percentages for
categorical or ordinal variables. Treatment groups were compared
using the exact Wilcoxon test for numeric or ordinal variables, the
Fisher exact test for binary variables, and the likelihood ratio test
Table 2. Treatment characteristics.
Category Subcategory All patients (n=71) RT alone (n =51) ChemoRT (n=20) p value
Radiation therapy given Brachytherapy alone 9 (13%) 9 (18%) 0 (0%) 0.006
EBRT alone 10 (14%) 10 (20%) 0 (0%)
EBRT+brachytherapy 52 (73%) 32 (63%) 20 (100%)
RT dose to Vagina (EQD2) All RT groups 68.2615.4 Gy 65.1616.8 Gy 76.066.5 Gy 0.99
Brachy alone group 54.2622.2 Gy 54.2622.2 Gy – –
EBRT alone group 48.467.1 Gy 48.467.1 Gy – –
EBRT+brachy group 74.469.3 Gy 73.5610.7 Gy 76.066.5 Gy 0.90
EBRT fields 4-field 25 (35%) 18 (35%) 7 (35%) 0.654
AP/PA 32 (45%) 21 (41%) 11 (55%)
Opposed laterals 1 (1%) 1 (2%) 0 (0%)
3-field 1 (1%) 0 (0%) 1 (5%)
En face 1 (1%) 1 (2%) 0 (0%)
Unknown 2 (3%) 1 (2%) 1 (5%)
Brachytherapy type Cylinder 26 (37%) 21 (41%) 5 (25%) 0.235
Interstitial 26 (37%) 16 (31%) 10 (50%)
Tandem and ovoid 4 (6%) 1 (2%) 3 (15%)
Cylinder and tandem 2 (3%) 1 (2%) 1 (5%)
Interstitial and tandem 2 (3%) 1 (2%) 1 (5%)
Sutures 1 (1%) 1 (2%) 0 (0%)
Brachytherapy dose rate HDR 23 (32%) 12 (24%) 11 (55%) 0.090
LDR 38 (54%) 29 (57%) 9 (45%)
Concurrent Chemotherapy Yes 20 (28%) – – –
Cisplatin 17 (24%) – 17 (85%)
Carboplatin 2 (3%) – 2 (10%)
5-FU 1 (1%) – 1 (5%)
Unknown 0 (1%) – 0 (0%)
Number of cycles chemo ChemoRT group 5 (1–8) – 5 (1–8) –
Surgery Yes 20 (28%) 18 (35%) 2 (10%) 0.040
Wide excision 7 (10%) 6 (12%) 1 (5%)
Vaginectomy 11 (16%) 10 (20%) 1 (5%)
Pelvic exenteration 2 (3%) 2 (4%) 0 (0%)
Key: CRT, concurrent chemoradiation; EBRT, external-beam radiation therapy; EQD2, Equivalent dose in 2Gy fractions; AP/PA, anterioposterior/posterioanterior; HDR,
high-dose-rate; LDR, low-dose-rate.
doi:10.1371/journal.pone.0065048.t002
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for multicategory discrete variables. Two-sided p-values ,0.05
were considered statistically significant. OS was measured from
the date of the start of RT to the date of death or last follow-up.
Survival curves were generated using the Kaplan-Meier method
and compared using the log-rank test. Univariate and multivariate
Cox regression analyses were used to identify predictors of OS and
DFS. Statistical analyses were performed using R, version 2.12.0.
Results
We identified 71 patients with primary vaginal cancer treated
with definitive RT with or without concurrent chemotherapy at
Brigham & Women’s Hospital/Dana-Farber Cancer Institute
between 1972 and 2009. A total of 51 patients were treated with
RT without chemotherapy and 20 were treated with CRT.
Patient and Tumor Characteristics
Detailed patient and tumor characteristics are listed in Table 1.
The median age was 61 years for all patients. There were no
significant differences between the RT-alone and CRT groups
with regard to FIGO stage, tumor size, histology, differentiation or
presence of LVI. There was a statistically significant difference in
terms of the year of diagnosis; more patients treated with RT alone
were diagnosed prior to 1999, and more patients treated with
CRT were diagnosed after 1999. With regard to tumor site, there
was a trend towards a higher proportion of patients in the CRT
group having involvement of the lower 1/3 of the vagina. A
significantly higher percentage of patients in the CRT group than
the RT-alone group underwent diagnostic imaging; also, signifi-
cantly more patients in that cohort had radiographically detected
lymph node involvement.
Treatment Details
Treatment characteristics for all patients are listed in Table 2. In
the RT-alone group, most patients were treated with EBRT and
brachytherapy, although some patients received EBRT alone or
brachytherapy alone. In the CRT group, all patients were treated
with both EBRT and brachytherapy. Twenty-eight percent of all
patients underwent surgery as part of their initial management
prior to RT or CRT, including 35% of patients in the RT-only
group and 10% of those in the CRT group. Most of these patients
underwent either a vaginectomy (16%) or a wide local excision of
tumor (10%).
The mean total radiation dose received for all patients,
calculated as the BED in 2-Gy fractions, was 68.2615.4 Gy.
The difference in radiation dose received between patients in the
RT-alone group and those treated with CRT was not statistically
significant (Table 2). The subgroup of patients treated with both
EBRT and brachytherapy received a higher total dose of radiation
(BED, 74.469.3 Gy) than those treated with EBRT alone;
however, this also did not significantly differ between the RT-
alone and CRT groups. The technique and field arrangements of
EBRT are described in Table 2. There were no significant
differences in technique between the RT-alone and CRT groups.
Most patients received EBRT with a 4-field approach or
anterioposterior/posterioanterior fields. With regard to brachy-
therapy technique, there was no significant difference in the types
of brachytherapy applicators used between the two groups.
However there was a trend towards a higher percentage of
patients in the CRT group receiving HDR brachytherapy as
opposed to low-dose-rate (LDR) brachytherapy.
Among the CRT patients, 85% received weekly cisplatin
concurrently with RT at a dose of 40 mg/m2; the remainder
received either carboplatin or 5-FU during RT. The average
number of cycles of concurrent chemotherapy completed was five.
One patient received adjuvant doxorubicin and paclitaxel after
completion of CRT with concurrent cisplatin. Another patient
received neoadjuvant cisplatin and 5-FU prior to undergoing
CRT with concurrent 5-FU. One patient who was included in the
RT-only group received carboplatin and cyclophosphamide prior
to her radiation.
Outcome
The median follow-up time among survivors was 3.0 years for
all patients. Median follow-up time was not significantly different
between the RT-alone and CRT groups (Table 1). Kaplan-Meier
actuarial OS rates at 3 years were 56% for the RT-alone group
and 79% for the CRT group (log-rank p=0.037; Figure 1).
Median OS time was 4.3 years for the RT-alone group and had
not been reached for the CRT group. DFS was also significantly
different between the two groups, with actuarial 3-year DFS rates
of 43% for the RT-alone group and 73% for the CRT group (log-
Figure 1. Overall survival by treatment (chemoradiation
therapy or radiation therapy alone).
doi:10.1371/journal.pone.0065048.g001
Figure 2. Disease-free survival by treatment (chemoradiation
therapy or radiation therapy alone).
doi:10.1371/journal.pone.0065048.g002
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rank p=0.011; Figure 2). Median DFS time was 1.9 years for the
RT-alone group and had not been reached for the CRT group.
A subgroup analysis was performed for the 52 patients who
received both EBRT and brachytherapy; 32 of these were in the
RT-alone group and 20 in the CRT group. Within this subgroup,
actuarial 3-year DFS rates remained significantly different
between the RT-alone and CRT groups (48% vs. 73%; log-rank
p=0.027) and actuarial 3-year OS trended towards a difference
favoring the CRT group (62% vs. 79%; log-rank p=0.113).
Patterns of Tumor Relapse
A total of 26 patients (37%) had a relapse of vaginal cancer after
treatment. With regard to the sites of first relapse, 10 patients
(14%) had local only, 4 (6%) had local and regional, 9 (13%) had
regional only, 1 (1%) had regional and distant, and 2 (3%) had
distant only relapse. The percentage of patients with relapse was
significantly higher in the RT-alone group (n= 23, 45%) than in
the CRT group (n= 3, 15%; p=0.027). The distribution of the
first sites of vaginal-cancer relapse is depicted in graphical form in
Figure 3.
Cox Proportional Hazards Analyses
Results from univariate Cox proportional hazards analyses for
DFS and OS are presented in Table 3. On univariate analysis for
predictors of DFS, year of diagnosis, use of concurrent chemo-
therapy, FIGO stage, and tumor size .4 cm were significant
variables. Variables that were not significant included lymph node
involvement, tumor differentiation, age at diagnosis, use of
surgery, prior hysterectomy, treatment duration, and use of 3D
diagnostic imaging. Significant univariate predictors of OS
included year of diagnosis, use of concurrent chemotherapy,
radiation dose (EQD2), use of both EBRT and brachytherapy,
Figure 3. Sites of first relapse by treatment group (radiation therapy alone compared to chemoradiation therapy).
doi:10.1371/journal.pone.0065048.g003
Table 3. Cox proportional hazards analyses.
Univariate Disease-Free Survival Overall Survival
Variable Crude HR (95% CI) P value (Wald) Crude HR (95% CI) P value (Wald)
Date of diagnosis (year) 0.96 (0.93–0.99) 0.011 0.96 (0.93–0.99) 0.030
Chemotherapy 0.28 (0.10–0.80) 0.017 0.30 (0.09–0.99) 0.049
FIGO stage 1.53 (1.08–2.16) 0.017 1.38 (0.95–2.00) 0.096
Tumor size .4 cm 2.12 (1.04–4.35) 0.040 1.84 (0.83–4.06) 0.131
Treatment duration (days) 0.99 (0.97–1.001) 0.072 0.98 (0.97–1.001) 0.062
3D Diagnostic imaging 0.54 (0.28–1.07) 0.077 0.67 (0.31–1.42) 0.295
Brachytherapy (any) 0.50 (0.22–1.10) 0.084 0.42 (0.18–0.97) 0.041
RT dose to vagina (.70 Gy EQD2) 0.55 (0.27–1.09) 0.085 0.34 (0.15–0.77) 0.009
Age at diagnosis 1.02 (0.99–1.04) 0.096 1.02 (0.999–1.04) 0.066
Prior hysterectomy 1.80 (0.89–3.62) 0.100 1.71 (0.81–3.60) 0.156
Tumor differentiation 0.71 (0.45–1.11) 0.130 0.65 (0.39–1.11) 0.107
EBRT and brachytherapy 0.59 (0.30–1.18) 0.138 0.44 (0.20–0.94) 0.034
Lymph node involvement 0.90 (0.35–2.32) 0.822 0.86 (0.30–2.49) 0.781
Surgery 0.99 (0.49–2.00) 0.980 0.93 (0.42–2.07) 0.866
Key: HR, hazard ratio; FIGO, Federation Internationale de Gynecologie et Obstetrique; EQD2, Equivalent dose in 2Gy fractions; EBRT, external-beam radiation therapy.
doi:10.1371/journal.pone.0065048.t003
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and any use of brachytherapy. Radiation dose was significant both
as a continuous variable and when dichotomized by the median
dose of 70 Gy. Lymph node involvement, tumor differentiation,
age at diagnosis, use of surgery, prior hysterectomy, treatment
duration, use of 3D diagnostic imaging, FIGO stage, and tumor
size were not significant univariate predictors of OS.
Given the total of 26 relapse events, the number of variables
that could be included in the multivariate model was limited. We
therefore tested several clinically relevant variables in combina-
tion, realizing that the final multivariate model would be
weakened by the small number of events. We included year of
diagnosis in the models to attempt to control for changes over
time. On including tumor size in a model for DFS that included
the use of concurrent chemotherapy, FIGO stage, and year of
diagnosis, tumor size was no longer significant, and the HR for
chemotherapy remained significant at 0.31 (95% CI 0.10–0.98;
p = 0.05). To assess the impact of 3D diagnostic imaging, this
variable was evaluated in the multivariate model for DFS. With
this exploratory analysis, the HR for the use of concurrent
chemotherapy remained significant at 0.31 (95% CI 0.10–0.97;
p = 0.04). However, the use of diagnostic imaging itself was not
significant on univariate analysis (HR 0.54; 95% CI, 0.28–1.07;
p=0.08) and was therefore not included in the final model.
Similarly, total RT dose to the vagina ($70 Gy EQD2) was not a
significant predictor for DFS on MVA. Therefore, our final
multivariate model for DFS included the use of chemotherapy,
FIGO stage, and year of diagnosis, with which the DFS hazard
ratio for the use of concurrent chemotherapy remained significant
at 0.31 (95% CI, 0.10–0.97; p = 0.04).
Discussion
This retrospective single-institution study demonstrates a
potential benefit in overall survival and disease-free survival with
the addition of concurrent chemotherapy in the treatment of
primary vaginal cancer. In addition to the use of concurrent
chemotherapy, other significant covariates in univariate models for
disease-free and overall survival included radiation dose, FIGO
stage, tumor size and year of diagnosis. Multivariate analysis was
limited given the small number of events. Whether concurrent
chemotherapy contributes to a long-term overall survival benefit in
patients who receive sufficient radiation in the modern era must be
tested in a larger study.
Prospective randomized controlled trials have demonstrated a
survival benefit with the addition of concurrent chemotherapy to
RT in the treatment of cervical cancer [10,11]. Other studies have
demonstrated the efficacy of CRT in the treatment of vulvar
cancer [15,16,17,18]. A number of retrospective studies have
examined the tolerability of and outcomes after chemoradiation
therapy in patients with primary vaginal cancer, but none have
had a comparative radiation-only group. Dalrymple and col-
leagues reported on a retrospective series of 14 patients with
squamous carcinoma of the vagina treated with CRT consisting of
5-FU, cisplatin or mitomycin-C; 9 patients were alive and cancer-
free 74–168 months after treatment [12]. Samant and colleagues
reported a similar retrospective series of 12 patients with primary
vaginal cancer treated with CRT, with a more homogeneous
treatment regimen consisting of concurrent weekly cisplatin [13].
The 5-year overall, progression-free, and locoregional-progres-
sion-free survival rates were 66%, 75%, and 92%, respectively, in
that series. Nashiro and colleagues reported on a smaller
retrospective series of 6 patients treated with cisplatin-based
CRT, of whom 4 remained free of disease at 18, 23, 33 and 55
months, respectively. [14] Our current study, with 51 RT-only
and 20 CRT patients, represents the largest series of chemoradia-
tion compared to radiation only for patients with primary vaginal
cancer treated at the same institution.
The management of vaginal cancer has changed in several ways
over the course of the study. Patients treated before 2002 received
LDR brachytherapy, whereas those treated from 2002 forward
received HDR brachytherapy. Prospective randomized trials in
cervical cancer have shown no difference in outcome between
LDR and HDR [19]. In addition, the advent of 3-D imaging since
the 1980s has enabled more accurate staging of vaginal cancer and
improved delineation of the tumor. In order to assess the impact of
3-D diagnostic imaging, this variable was assessed as a potential
confounder. In a multivariate model, diagnostic imaging was not
significant, whereas CRT remained significant in the final model,
indicating the independent predictive role of the use of CRT. The
introduction of 3-D imaging has also allowed the implementation
of image-guided adaptive brachytherapy approaches over the past
decade [2]. Since 2002, our institution has used MRI guidance
followed by MR- and CT-based treatment planning for vaginal
brachytherapy treatment [20,21]. In the current study, the
prescription dose was 74.4+/29.3 Gy EQD2 for patients treated
with EBRT and brachytherapy. The question of whether patients
treated with an adequate dose of radiation, using image-based
conformal brachytherapy planning, benefit from concurrent
chemotherapy must be assessed in larger clinical trials. Chemo-
therapy does cause rapid regression of the tumor, resulting in
treatment of a small radiation volume. This smaller tumor volume
may reduce the amount of rectal tissue exposed to radiation, and
the D2cc (dose to 2cc of rectum) predicts for the risk of future
rectal morbidity [22].
A previous study using RT alone for vaginal cancer demon-
strated excellent 5-year DFS rates of 82% for tumors ,4 cm and
60% for tumors .4 cm [6]. It also demonstrated stage-dependent
locoregional relapse rates of 68% for Stages I–II and 83% for
Stages III–IVA [6]. Our study showed a 3-year DFS rate of 73%
for all patients receiving CRT.
Limitations of our study include its retrospective nature, its
scope as a single institutional experience, and its inclusion of
patients who were treated over a long period. The year of
diagnosis was therefore included in the analysis to account for
shifts in technology and treatments over time, some of which are
known confounders and others that may be unknown. Therefore,
appropriate adjustment for year of diagnosis in the multivariate
modeling was valuable.
Our data suggest that chemoradiation therapy may be
considered in the treatment of patients with primary vaginal
cancer. Adequate radiation dosing with the combination of
external beam and brachytherapy is critical to the curative
management of patients. Though accrual may require interna-
tional collaboration, prospective trials may be warranted to more
thoroughly assess the benefit of adding concurrent chemotherapy
to radiation therapy in these patients.
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